BRCA2, ATM, and CDK12 defects differentially shape prostate tumor driver genomics and clinical aggression.

DNA damage repair (DDR) defects are common across cancer types and can indicate therapeutic vulnerability. Optimal exploitation of DDR defects in prostate cancer requires new diagnostic strategies and a better understanding of associated clinical-genomic features.